Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05283330 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
A Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer, sponsored by Orano Med.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 4
- Study locations
NCT05283330: Recruiting Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer, sponsored by Orano Med.
NCT05283330 is a Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer that is actively recruiting participants, run by Orano Med. The registered enrollment target is 48 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05283330, a Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by Orano Med.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 4
- Study locations
Study Summary
A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or Metastatic GRPR-expressing Tumors
Primary Outcome
Incidence of DLTs.
Conditions Studied
Interventions
- DRUG ²¹²Pb-DOTAM-GRPR1
Study Locations (4)
Illinois
- Northwestern University Robert H Lurie Medical Research - Chicago
Kentucky
- UK Markey Cancer Center - Lexington
Maryland
- Advanced Molecular Imaging and Therapy - Glen Burnie
Nebraska
- XCancer Omaha / Urology Cancer Center - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2022-12-22 |
| Est. Completion | 2032-05 |
| Phase | Phase 1 |
What NCT05283330 shows while recruiting
NCT05283330 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower).
The record links to 7 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which ²¹²Pb-DOTAM-GRPR1 is the first listed.
NCT05283330 reports a single indexed study location in Illinois, Kentucky, Maryland.
Frequently Asked Questions
What is clinical trial NCT05283330 about?
NCT05283330 is a clinical study titled "Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors". A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or Metastatic GRPR-expressing Tumors
What is the current status of trial NCT05283330?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2022-12-22. Estimated completion is 2032-05.
What conditions does trial NCT05283330 study?
This clinical trial studies the following conditions: Breast Cancer, Non-Small Cell Lung Cancer, Glioblastoma, Cervical Cancer, Colon Cancer.
What interventions are being tested in trial NCT05283330?
The interventions under investigation include: ²¹²Pb-DOTAM-GRPR1 (DRUG).
Who is sponsoring clinical trial NCT05283330?
This trial is sponsored by Orano Med, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05283330 being conducted?
This trial has 4 study locations across Illinois, Kentucky, Maryland, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05283330's enrollment target sits among peer trials
48 821st of 1224 higher than 394 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI